

Saudi Arabian Mining Co. (Ma'aden) (1211.SE)

Rating	OUTPERFORM*
Price (28 Oct 08, SAR)	13.05
Target Price (SAR)	36.57 ¹
Market cap. (SRIs m)	12,071.25
Enterprise value (SRIs m)	8,220.7

*Stock ratings are relative to the relevant country index.
¹Target price is for 12 months.

Research Analysts


Zeid Massad
+971 4 362 0187
zeid.massad@credit-suisse.com

COMPANY UPDATE

Flush with cash, phosphate project on track

- **Event:** Ma'aden reported its first results in 2008 after going public in July of 2008. Credit Suisse global agricultural team updates its global short-/mid-term phosphate outlook.
- **Q3 2008 in line:** reported SAR 64m vs. our estimate of SAR70m, a (130% increase YOY). No production figures were posted yet, but the increase from last year is probably attributable to (1) higher realized gold prices after starting out 2008 with a clean commodity hedge book and (2) receiving over SAR10bln of IPO and privatisation proceeds in Q3, and earning investment income on idle cash.
- **9-month bottom line dwarfed by one-time privatisation costs:** While gross profits were up 234% YOY, Ma'aden reported an operating loss of SAR37m vs our estimate of SAR198m profit, due to expensing Ma'aden's IPO/privatisation costs.
- **Flush with cash, phosphate project finance secured:** Ma'aden has already secured over US\$3.8bln of project financing to fund the debt component of its US\$5.5 phosphate project. Q3 2008 balance sheet headlines indicate SAR13bln of current assets after the company receives IPO proceeds. As per the company's latest statement, the project and supporting railway is still on track for a late 2010 launch of the world's upcoming largest and lowest cost fully integrated rock to fertiliser Diammonium phosphate (DAP) production facility.
- **We update our fertiliser forecasts; effect on Ma'aden's estimates:** We revise Credit Suisse's short- to mid-term phosphate fertiliser outlook downwards. This has no bearing on Ma'aden's valuation, as our assumptions for production starting in 2011 are in line with current long-term assumptions.
- **Valuation:** We maintain our Outperform recommendation and our SAR36.57/sh price target.

Share price performance



The price relative chart measures performance against the MSCI Arabian markets index - GCC CI index which closed at 523.29 on 24/10/08

On 24/10/08 the spot exchange rate was SAR4.73/Eu 1. - Eu 0.79/US\$1

Performance Over	1M	3M	12M
Absolute (%)	-34.4	-57.2	—
Relative (%)	-15.6	-31.2	—

Financial and valuation metrics

Year	12/07A	12/08E	12/09E	12/10E
Revenue (SAR m)	244.1	635.1	710.3	724.6
EBITDA (SAR m)	6.90	608.09	551.43	538.20
Net Income (SAR m)	-26.5	268.3	211.7	-286.4
CS adj. EPS (SAR)	-0.03	0.29	0.23	-0.31
ROIC (%)	—	—	—	—
P/E (adj., x)	-454.73	45.00	57.01	-42.15
P/E rel. (%)	—	—	—	—
EV/EBITDA	1,754.5	18.0	36.9	53.2
Dividend (2007A, SAR)	—	IC (12/08E, SAR m)	—	—
Dividend yield (%)	—	EV/IC	—	—
Net debt (12/08E, SAR m)	-3,850.5	Current WACC	—	9.0
Net debt/equity (12/08E, %)	-25.6	Free float (%)	—	50.0
BV/share (12/08E, SAR)	16.3	Number of shares (m)	—	925.00

Source: Company data, Thomson Financial Datastream, Credit Suisse estimates.

Phosphorus: Visibility Is Low, but the Evidence Is Bullish

Nutrients are commodities, and for the most part, when demand falls, prices fall with them. But as we have argued for more than a year, the market structure in phosphorus is far better than many investors, and some in the industry, tend to believe. Among all the nutrients, we think the risk/reward balance is strongest in phosphorus right now, despite lower-than-expected near-term visibility.

In late August, it became evident that Brazil's distribution system was backing up—with both phosphorus and potash. Producers across the globe knew it, but didn't worry much about it (because it was a slow season, and most indicators were positive). Demand from India was robust, and, by most accounts, India's pipeline is still not full. But the credit crunch, coupled with a late planting season for winter wheat in the US, meant that the pipeline would not (and did not) clear in October, as most had assured themselves (and each other) that it would.

US farmers saw an opportunity, and like farmers in Parana, Brazil, they are exploiting it exactly as they should. By delaying purchases, they hope to break the supply discipline in phosphorus that some big players have sometime suggested isn't as strong as it should be.

So will it work? Will a "buyers strike" break the will of phosphorus producers who tend to like to keep their facilities running? The evidence says that both sides will win—prices will go down, but profits should still improve, thanks to sharply lower costs. Mosaic's promise of up to a 1mm-ton production cut should keep the US market fairly tight. PotashCorp hasn't set a number, but says it remains fully committed to supply discipline (PotashCorp practically invented supply discipline in fertilizer). But the North American players are only about 27% of global phosphorus, and as PotashCorp likes to remind investors, there are a lot more phosphorus players than potash producers.

However, outside North America the situation is better than it appears. Many of those producers (like China) have limited reserves (China's are estimated at 30 years). So while there are many, they aren't inclined to blow through their reserves quickly, and certainly not at low prices (not when ag self-sufficiency is a goal). Will China run for cash and become a big exporter as new capacity comes on line? Not unless they want to be a net buyer in two decades (that wouldn't square well with their self-sufficiency goals).

Which brings us to OCP. Morocco has some of the world's best and biggest rock reserves. Will OCP run for cash and flood the market? In the past, it would have been tough to guess, but recently OCP has announced production cutbacks to balance supply and demand, and appears to be making good on those promises. While there isn't a track record there, producer behavior clearly suggests that big players are going to give supply discipline a try. While our price forecasts assume a considerable drop in rock prices, the potential for producers to outperform these forecasts is higher, we believe, than in the other nutrients. We remain fundamentally bullish on phosphorus; our targets reflect the lack of track record and visibility, at a time when investor confidence is not high.

Does supply discipline carry political risk? Will these producers be tagged as bad guys? If global food supply dwindles, we would expect some political pressure, but remember that the increase in fertilizer margins are the reason we have so many capacity expansions—clamp down on fertilizer profits, and you can expect a decline in fertilizer reinvestment that, on a global basis, we can't afford.

MAP & DAP: Costs Down, Profits Down Less

Supply discipline, as we see it, is better than ever in phosphorus. But sulfur prices are down 70% in for the fourth quarter on a contract basis (and headed the same direction in

North America). Rock prices have peaked, and are certainly headed lower. *But the notion that rock prices are headed to cash cost is mistaken, we believe*—neither the North American nor the Moroccan producers can justify their expansion plans at low rock prices. But with producers costs coming down (particularly via sulfur, but also in rock and energy), both sides can get what they want—customers get lower prices, and producers can get relatively strong margins. That balance may be upset later if input costs rise again, but for now DAP looks like a win-win situation (for the big, low cost producers, at least).

Certainly, lower sulfur costs are going to benefit producers; but customers may push for lower prices too. The big driver remains phosphate rock, multiples of which are required per tonne of DAP compared with sulfur or ammonia. So, just as long as phosphate rock producers stay disciplined (read, mimic their potash cousins) and allow rock prices to drop, but not to cash cost level, then there will still be plenty of margin in the chain.

“Let’s just skip a year?”

The issue of demand destruction is much more complex in phosphorus. Unlike nitrogen, the need for and optimal application rates for phosphorus aren’t as well understood in many emerging economies. And while we hear lots of stories about phosphates polluting rivers and streams (algae blooms like the one China saw just ahead of the Olympics are often caused by phosphate run-off), the reality is that phosphorus stays in the soil better than nitrogen.

Thus, where soil tests indicate that there is enough, it is likely that some farmers will cut back. But with the high cost of phosphorus, it is unlikely that too many farmers have been overapplying (soil testing helps avoid that). In other regions, where soil testing is less widespread, excess phosphorus is generally even less likely. Still, with prices down, farmers may well decide to sacrifice some yield and quality this year to cut costs.

Then there is the feed issue. Defluorinated phosphate (DFP) is a staple of chicken and pig feed in commercial production, and the financial struggle of US chicken farmers has been well documented. On the flip side, China has made a major push for more pigs, to counter the pork price inflation they experienced in 2008. Add to that the threat of global recession, and demand for grain and DFP feed for protein production may well be depressed in 2009 (10/22/2008, Impact of Credit Crises on Protein Consumption, R. Moskow).

So where does all this end up? Demand will certainly be down in Q4/08, and probably through the first part of 2009. But costs will be down too, fairly dramatically (sulfur, rock and transportation). For the highest cost producers, who tend to set the market price, this is very good news (they couldn’t afford to see prices fall without costs coming down). For farmers feeling the pinch of low grain prices, the news is welcome relief. And for the lower cost producers (Maaden, Mosaic, etc.), the news is just fine...

Exhibit 1: Phosphate Price Forecast

Exhibit 1: Phosphate Price Forecast							
Product	2006A	2007A	2008E	2009E		2010E	
				Old	New	Old	New
Phosphates							
Central Florida DAP \$/st	\$225	\$364	\$1,163	\$1,313	\$600	\$1,298	\$630
U.S. Gulf Export (\$/mt)	261	419	1,271	1,421	660	1,406	690
North Africa Phosphate Rock (\$	44	59	338	480	200	480	200
Sulfur							
Tampa Sulfur (\$/LT)	\$68	\$72	\$406	\$535	\$175	\$525	\$164

Source: Credit Suisse estimates, Fertecon, Green Markets

We consider our phosphate forecasts to be conservative, relative to our other forecasts, particularly in light of the evidence of supply discipline. Our caution reflects the lack of a track record. Moreover, integrated producer margins remain robust.

Companies Mentioned (Price as of 27 Oct 08)

Saudi Arabian Mining Co. (1211.SE, SRIsr16.00, OUTPERFORM, TP SRIsr36.57)


Disclosure Appendix

Important Global Disclosures

The analysts identified in this report each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

See the *Companies Mentioned* section for full company names.

3-Year Price, Target Price and Rating Change History Chart for 1211.SE



The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities.

Analysts' stock ratings are defined as follows***:

Outperform (O): The stock's total return is expected to exceed the industry average* by at least 10-15% (or more, depending on perceived risk) over the next 12 months.

Neutral (N): The stock's total return is expected to be in line with the industry average* (range of $\pm 10\%$) over the next 12 months.

Underperform (U):** The stock's total return is expected to underperform the industry average* by 10-15% or more over the next 12 months.

*The industry average refers to the average total return of the relevant country or regional index (except with respect to Europe, where stock ratings are relative to the analyst's industry coverage universe).

**In an effort to achieve a more balanced distribution of stock ratings, the Firm has requested that analysts maintain at least 15% of their rated coverage universe as Underperform. This guideline is subject to change depending on several factors, including general market conditions.

***For Australian and New Zealand stocks a 7.5% threshold replaces the 10% level in all three rating definitions, with a required equity return overlay applied.

Restricted (R): In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V]: A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' coverage universe weightings are distinct from analysts' stock ratings and are based on the expected performance of an analyst's coverage universe* versus the relevant broad market benchmark**:

Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

*An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

**The broad market benchmark is based on the expected return of the local market index (e.g., the S&P 500 in the U.S.) over the next 12 months.

Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution		
Outperform/Buy*	41%	(59% banking clients)
Neutral/Hold*	44%	(57% banking clients)
Underperform/Sell*	13%	(50% banking clients)
Restricted	2%	

*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research-and-analytics/disclaimer/managing_conflicts_disclaimer.html

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

See the Companies Mentioned section for full company names.

Price Target: (12 months) for (1211.SE)

Method: We used a DCF with a WACC of 9% over the expect life for Ma'aden's projects.

Risks: 1) Commodity risk: decline in commodities could affect cash-flows and valuations. 2) Project cost escalation risk: aluminum project runs this risk as building costs have not been locked-in, as is the case for the phosphate project. 3) Corporate governance/government risk: the Saudi government holding a 50% stake has the potential to affect Ma'aden's operations. 4) China policy reversal: if China removes its current tariffs on fertilizer exports, prices for DAP could fall, potentially affecting Ma'aden's cashflows and valuations.

Important Regional Disclosures

The analyst(s) involved in the preparation of this report have not visited the material operations of the subject company (1211.SE) within the past 12 months.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

Principal is not guaranteed in the case of equities because equity prices are variable.

Commission is the commission rate or the amount agreed with a customer when setting up an account or at anytime after that.

To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors:

The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

- Zeid Massad, non-U.S. analyst, is a research analyst employed by Credit Suisse Securities (Europe) Limited.

For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at www.credit-suisse.com/researchdisclosures or call +1 (877) 291-2683.

Disclaimers continue on next page.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse, the Swiss bank, or its subsidiaries or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates.

The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. CS does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change.

CS believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in the other sections of the report were obtained or derived from sources CS believes are reliable, but CS makes no representations as to their accuracy or completeness. Additional information is available upon request. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected total return over a 12-month period as defined in the disclosure section. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. In addition, CS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. CS is involved in many businesses that relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage, market making, and other proprietary trading.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk.

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase.

Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment, in such circumstances you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed.

This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk.

This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is regulated in the United Kingdom by The Financial Services Authority ("FSA"). This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States by Credit Suisse Securities (USA) LLC ; in Switzerland by Credit Suisse; in Canada by Credit Suisse Securities (Canada), Inc.; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A.; in Japan by Credit Suisse Securities (Japan) Limited, Financial Instrument Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Equities (Australia) Limited, Credit Suisse Securities (Thailand) Limited, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse Singapore Branch, Credit Suisse Securities (India) Private Limited, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse Taipei Branch, PT Credit Suisse Securities Indonesia, and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse Taipei Branch has been prepared by a registered Senior Business Person. Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn. Bhd., to whom they should direct any queries on +603 2723 2020.

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S.

Please note that this report was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA or in respect of which the protections of the FSA for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

Any Nielsen Media Research material contained in this report represents Nielsen Media Research's estimates and does not represent facts. NMR has neither reviewed nor approved this report and/or any of the statements made herein.

If this report is being distributed by a financial institution other than Credit Suisse, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content.

Copyright 2008 CREDIT SUISSE and/or its affiliates. All rights reserved.

CREDIT SUISSE SECURITIES (Europe) Limited
Europe: +44 (20) 7888-8888